U.S. to Buy Enough of Pfizer’s Covid Antiviral Pills for 10 Million Peoplenews2021-11-17T02:47:01+00:00November 17th, 2021|The New York Times|
F.D.A. Plans to Authorize Pfizer Boosters for All Adults This Weeknews2021-11-17T01:17:59+00:00November 17th, 2021|The New York Times|
Pfizer Asks F.D.A. to Authorize Covid Pill For High-Risk Unvaccinated Peoplenews2021-11-17T00:40:29+00:00November 17th, 2021|The New York Times|
Pfizer Will Allow Its Covid Pill to Be Made and Sold Cheaply in Poor Countriesnews2021-11-16T21:00:17+00:00November 16th, 2021|The New York Times|
AstraZeneca Says it Will Start Profiting From its Vaccinenews2021-11-13T05:15:23+00:00November 13th, 2021|The New York Times|
Johnson & Johnson Will Break Itself Up Into Two Companiesnews2021-11-12T22:49:01+00:00November 12th, 2021|The New York Times|
Antony Blinken Says ‘We Have Fallen Short’ on Global Vaccine Distributionnews2021-11-10T18:28:19+00:00November 10th, 2021|The New York Times|
Moderna and U.S. at Odds Over Vaccine Patent Rightsnews2021-11-10T00:23:03+00:00November 10th, 2021|The New York Times|
Pfizer Says Its Antiviral Pill Is Highly Effective in Treating Covidnews2021-11-05T19:13:46+00:00November 5th, 2021|The New York Times|
U.K. Authorizes Merck’s Antiviral Pill for Covid-19news2021-11-04T17:42:59+00:00November 4th, 2021|The New York Times|
